Home
»
Press Room
»
Antibody Production Market To Reach $39.80Bn By 2033

Antibody Production Market To Reach $39.80 Billion By 2033

September 2025 | Report Format: Electronic (PDF)

Antibody Production Market Growth & Trends

The global antibody production market size is estimated to reach USD 39.80 billion by 2033, registering to grow at a CAGR of 11.2% from 2025 to 2033, according to a new report by Grand View Research, Inc. Due to the rising incidence of chronic illnesses such as cancer, diabetes, and cardiovascular diseases, as well as the increased need for therapeutic antibodies the antibody production market is anticipated a significant growth.

Nearly half of all R&D programs related to monoclonal antibodies are allocated for cancer treatment. The focused approach of monoclonal antibodies has transformed cancer treatment by minimizing adverse effects and enhancing patient outcomes. Nevertheless, further research and development are crucial to maximize the effectiveness of antibodies in treating cancer. The market for antibody production is anticipated to experience growth due to the escalated investment in research and development activities, particularly in cancer treatment. Moreover, the demand for personalized medicine, which seeks to offer customized treatments based on an individual's genetic composition, lifestyle, and environmental influences, is anticipated to boost the antibody production market's growth.

The antibody production market was greatly influenced by the COVID-19 pandemic due to the increasing popularity of common laboratory tests like immunohistochemistry, cell imaging, and western blot analysis for diagnosis. Additionally, with the urgent need for therapeutic antibodies and vaccines to combat the virus, there has been a surge in demand for antibody production services. However, disruptions in the global supply chain and manufacturing processes caused by lockdowns, travel restrictions, and workforce shortages have posed significant challenges to the market's growth. Despite the challenges, the antibody production market has demonstrated resilience, and many companies have adapted their operations to continue serving customers during the pandemic.

Furthermore, the antibody production market is expected to grow due to the increasing demand for personalized medicine, which aims to provide tailored treatments based on an individual's genetic makeup, lifestyle, and environmental factors. Monoclonal antibodies are essential tools in personalized medicine, as they can be designed to target specific disease-causing proteins or cells. The growing demand for personalized medicine is expected to further drive the growth of the antibody production market. Additionally, the rise in the approval of antibodies for the treatment of cancer and various diseases is also contributing to market growth, as demonstrated by the U.S. FDA's emergency use authorization (EUA) for a monoclonal antibody, bebtelovimab, which retains activity against the omicron variant and is used for the treatment of COVID-19.

key Request a free sample copy or view report summary: Antibody Production Market Report

Antibody Production Market Report Highlights

Based on product, the consumables segment dominated in terms of the revenue share of 55.91% in 2024. This is attributed to growing demand for antibodies for study, diagnostics, and therapeutics, which has steered to a corresponding rise in the demand for consumables.
The downstream segment led the antibody production market in 2024 and is projected to grow at the fastest CAGR of 11.9% from 2025 to 2033.
In 2024, North America dominated with a revenue share of 37.78%, owing to the rising investments in drug discovery, growing developments in biopharmaceutical research, and the presence of major key players are anticipated to drive the growth of the antibody production market in this region.
Asia Pacific accounted for the fastest-growing region with a CAGR of 13.5% from 2025 to 2033. The growing investments in R&D activities and the increasing prevalence of chronic diseases are driving the rising demand for the antibody production market in this region.
Monoclonal antibody segment is anticipated to dominate the antibody production market with a significant revenue share in 2024 and is anticipated to grow at the fastest CAGR of 12.1% during 2025-2033.
Based on end use, the pharmaceutical and biotechnology companies segment dominates in terms of the revenue share of 55.06% in 2024. The expanding use of antibodies in the production processes of biopharmaceutical companies is considered one of the primary factors driving the growth of this segment.

Antibody Production Market Segmentation

Grand View Research has segmented the global antibody production market based on product, process, type, end use, and region:

Antibody Production Product Outlook (Revenue, USD Million, 2021 - 2033)

Instruments
- Bioreactors
  - Multi-use Bioreactors
  - Single-use bioreactors
- Chromatography systems
- Filtration systems
Consumables
- Media
- Buffers and reagents
- Chromatography resins and columns
- Filtration consumables and accessories
- Others
Software